American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 425-434 , March 2008

Delivery of Multifactorial Interventions by Nurse and Dietitian Teams in a Community Setting to Prevent Diabetic Complications: A Quality-Improvement Report

  • Peter A. Senior, MBBS, PhD

      Affiliations

    • Division of Endocrinology, University of Alberta, Edmonton AB, Canada
    • Corresponding Author InformationAddress correspondence to Peter A. Senior, MBBS, PhD, #2000 College Plaza, 8215 112 St, Edmonton AB, T6G 2C8, Canada.
    • ,
  • Laurel MacNair, MEd, NP, CDE

      Affiliations

    • Northern Alberta Renal Program, Capital Health, Edmonton AB, Canada
    • ,
  • Kailash Jindal, MD

      Affiliations

    • Northern Alberta Renal Program, Capital Health, Edmonton AB, Canada
    • Division of Nephrology, University of Alberta, Edmonton AB, Canada.

Received 9 July 2007 ,Accepted 14 November 2007.

References 

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  2. El Nahas M. The global challenge of chronic kidney disease. Kidney Int. 2005;68:2918–2929
  3. Massi-Benedetti M. The cost of diabetes type II in Europe: The CODE-2 Study. Diabetologia. 2002;45(suppl):S1–S4
  4. CORR Report: Dialysis and Renal Transplantation, 2001. Ottawa, Canada: Canadian Institute for Health Information; 2001;
  5. Schaubel DE, Morrison HI, Desmeules M, Parsons DA, Fenton SS. End-stage renal disease in Canada: Prevalence projections to 2005. CMAJ. 1999;160:1557–1563
  6. Ploth DW, Shepp PH, Counts C, Hutchison F. Prospective analysis of global costs for maintenance of patients with ESRD. Am J Kidney Dis. 2003;42:12–21
  7. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–1720
  8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713
  9. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J. 1982;285:685–688
  10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy (The Collaborative Study Group). N Engl J Med. 1993;329:1456–1462
  11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22
  13. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  15. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998;317:720–726
  16. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41) (United Kingdom Prospective Diabetes Study Group). BMJ. 2000;320:1373–1378
  17. Hendry BM, Viberti GC, Hummel S, Bagust A, Piercy J. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM. 1997;90:277–282
  18. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171:1189–1192
  19. Johnson JA, Vermeulen SU. Epidemiological trends of diabetes in Alberta, in Alberta Diabetes Atlas 2007. In: Edmonton, Alberta: Institute of Health Economics; 2007;p. 11–24
  20. Johnson JA, Rabi DM, Edwards AL, Vermeulen SU. Diabetes and health care utilization in Alberta, in Alberta Diabetes Atlas 2007. In: Edmonton, Alberta: Institute of Health Economics; 2007;p. 25–44
  21. New JP, Mason JM, Freemantle N, et al. Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): A randomized controlled trial. Diabetes Care. 2003;26:2250–2255
  22. Aubert RE, Herman WH, Waters J, et al. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization (A randomized, controlled trial). Ann Intern Med. 1998;129:605–612
  23. Kapur V, Basu K. Drug coverage in Canada: Who is at risk?. Health Policy. 2005;71:181–193
  24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  25. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  26. Toobert DJ, Glasgow RE. Assessing diabetes self management. In:  Bradley C editors. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. New York, NY: Psychology Press; 1994;p. 351–375

PII: S0272-6386(07)01586-7

doi: 10.1053/j.ajkd.2007.11.012

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 425-434 , March 2008

Article Tools

* Image Usage & Resolution